Scott David Ramsey

Scott David Ramsey

Auto-generated profile, based on publicly available information

Scott David Ramsey

Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SRScott D. Ramsey
Scott D. Ramsey
ABAasthaa Bansal
Aasthaa Bansal
CFCatherine R. Fedorenko
Catherine R. Fedorenko
DBDavid K. Blough
David K. Blough
KOKaren A. Overstreet
Karen A. Overstreet
PNPolly Newcomb
Polly Newcomb
Purpose: Patients with cancer are more likely to file for bankruptcy than the general population, but the impact of severe financial distress on health outcomes among patients with cancer is not known.Methods: We linked Western Washington SEER Cancer Registry records with federal bankruptcy records for the region. By using propensity score matching to account for differences in several demographic and clinical factors between patients who did and did not file for bankruptcy, we then fit Cox proportional hazards models to examine the relationship between bankruptcy filing and survival.Results: Between 1995 and 2009, 231,596 persons were diagnosed with cancer. Patients who filed for bankruptcy (n = 4,728) were more likely to be younger, female, and nonwhite, to have local- or regional- (v distant-) stage disease at diagnosis, and have received treatment. After propensity score matching, 3,841 patients remained in each group (bankruptcy v no bankruptcy). In the matched sample, mean age was 53.0 years, 54% were men, mean income was $49,000, and majorities were white (86%), married (60%), and urban (91%) and had local- or regional-stage disease at diagnosis (84%). Both groups received similar initial treatments. The adjusted hazard ratio for mortality among patients with cancer who filed for bankruptcy versus those who did not was 1.79 (95% CI, 1.64 to 1.96). Hazard ratios varied by cancer type: colorectal, prostate, and thyroid cancers had the highest hazard ratios. Excluding patients with distant-stage disease from the models did not have an effect on results.Conclusion: Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality. Further research is needed to understand the process by which extreme financial distress influences survival after cancer diagnosis and to find strategies that could mitigate this risk.

1 March 2015 in Value in Health
Verified
Journal Article
Closed access
SRScott D. Ramsey
Scott D. Ramsey
RWRichard J. Willke
Richard J. Willke
HGHenry Glick
Henry Glick
SRShelby D. Reed
Shelby D. Reed
FAFederico Augustovski
Federico Augustovski
SSSean D. Sullivan
Sean D. Sullivan

1 June 2013 in Health Affairs
Verified
Journal Article
Closed access
SRScott Ramsey
Scott Ramsey
DBDavid Blough
David Blough
AKAnne C Kirchhoff
Anne C Kirchhoff
KKKarma Kreizenbeck
Karma Kreizenbeck
CFCatherine Fedorenko
Catherine Fedorenko
KOKaren Overstreet
Karen Overstreet
Much has been written about the relationship between high medical expenses and the likelihood of filing for bankruptcy, but the relationship between receiving a cancer diagnosis and filing for bank...

1 September 2005 in Value in Health
Verified
Journal Article
Closed access
SRScott Ramsey
Scott Ramsey
RWRichard Willke
Richard Willke
ABAndrew Briggs
Andrew Briggs
RBRuth Brown
Ruth Brown
MBMartin Buxton
Martin Buxton
SRShelby Reed
Shelby Reed

27 March 2006 in Cancer
Verified
Journal Article
Open access
PDF file
SZSteven B. Zeliadt
Steven B. Zeliadt
SRScott D. Ramsey
Scott D. Ramsey
DPDavid F. Penson
David F. Penson
IHIngrid J. Hall
Ingrid J. Hall
DEDonatus U. Ekwueme
Donatus U. Ekwueme
JLJudith W. Lee
Judith W. Lee
Treatment choices for localized prostate cancer appear to vary widely, although it is unclear whether this variation is a result of patient values or other factors. The authors conducted a systematic review of the literature, identifying 70 articles that focused on prostate cancer decision making. Studies suggest that men consider several issues when making treatment decisions. The authors found conflicting evidence regarding the importance that men place on cancer eradication, with considerable variation in how patients interpret evidence regarding treatment efficacy. The number of physicians that men see and the importance of the physician recommendation were found to vary considerably. Although men stated that side effects are important, few patients reported that side effect factors ultimately influenced their treatment choice. To the authors' knowledge, there is little research regarding how patients' personal values shape and influence their decision, or the role of race/ethnicity or socioeconomic status in preferences for treatment. The authors conclude that variations in treatment decisions may be more indicative of differences in the information patients receive rather than truly reflective of underlying patient preferences. Considerable progress is needed in helping patients fully understand how to balance the complex issues surrounding prostate cancer treatment decision making. Cancer 2006. © 2006 American Cancer Society.

20 April 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JUJoseph M. Unger
Joseph M. Unger
AMAnna B. Moseley
Anna B. Moseley
CCChristabel K. Cheung
Christabel K. Cheung
RORaymond U. Osarogiagbon
Raymond U. Osarogiagbon
BSBanu Symington
Banu Symington
DHDawn L. Hershman
Dawn L. Hershman
PURPOSE: Patients with cancer living in socioeconomically disadvantaged areas have worse cancer outcomes. The association between socioeconomic deprivation and outcomes among patients with cancer participating in clinical trials has not been systematically examined.METHODS: We examined survival outcomes for patients enrolled in phase III and large phase II clinical trials for major cancers conducted by the SWOG Cancer Research Network from 1985 to 2012. Socioeconomic deprivation was measured using trial participants' residential zip codes linked to the Area Deprivation Index (ADI). Five-year overall survival, progression-free survival, and cancer-specific survival were examined using Cox regression frailty models, adjusting for age, sex, and race, and separately for insurance status, prognostic risk, and rural or urban residency.RESULTS: We examined 41,109 patients from 55 trials comprising 24 cancer histology and stage-specific cohorts. Compared with trial participants in the most affluent areas (ADI, 0%-20%), trial participants from areas with the highest socioeconomic deprivation (ADI, 80%-100%) had worse overall (hazard ratio [HR] = 1.28, 95% CI, 1.20 to 1.37, P < .001), progression-free (HR = 1.20, 95% CI, 1.13 to 1.28, P < .001), and cancer-specific survival (HR = 1.27, 95% CI, 1.18 to 1.37, P < .001). The results were similar after adjusting for insurance status, prognostic risk, and rural or urban residency. There was a continuous increase in risk of all outcomes as the ADI quintile increased.CONCLUSION: In patients with cancer with access to protocol-directed care in clinical trials, high area-level socioeconomic deprivation was associated with worse survival. Future research should examine whether the etiology of this residual disparity is related to reduced access to supportive care or postprotocol therapy and/or to differences in health status not reflected by protocol selection criteria.